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Background
Increasing evidence has supported the hypothesis that
cancer development is influenced by the host immune
system. The number, type and location of the immune
cells infiltrating the tumor microenvironment (TILs)
may either limit or promote tumor progression [1].
These observations have led to the development of
potential new scoring systems derived from the immune
context in tissue and based on the identification and
evaluation of specific lymphocyte populations. We
focused on the potential prognostic value of CD3, CD8,
CD20, and FOXP3 as an ‘Immunoscore’ for melanoma
patients which would utilize widely accessible, standar-
dized technology [2].
Methods
We collected FFPE lymphadenectomies from 34 mela-
noma patients, analyzing a total of 150 lymphnodes. We
have characterized the Immunescore by IHC expression of
CD3, CD8, CD20 and Foxp3 (all Ventana Medical Sys-
tems). 3-4 micrometers serial tissue sections have been cut
for H&E and stained with a multiplex of all markers
including tumor marker for melanoma (S100). Tissue sec-
tions were stained using novel multiplex staining protocols
on a VENTANA Benchmark instrument as well as serial
staining. For each case, manual cell counts and regional
annotation were taken. The number of positive cells has
been evaluated by counting them in 5 peritumoral and 5
intratumoral non-overlapping fields using X400 magnifica-
tion. The expression of each marker as well as combina-
tions of markers have been matched with the most
important clinical information of patients evaluating corre-
lation with clinical outcome.
Results
The data for each patient were summarized as a median
expression across sampled nodes, and these values were
then compared between relapse and no relapse groups.
There were statistically significant differences in the
peri/intra ratio for both CD3 and CD8, with the ratio
being higher in no relapse patients compared to relapse
patients for both proteins. These trending differences
also seemed apparent for both FoxP3 and CD20,
although our limited sample size limited some conclu-
sions. We then hypothesized a high/low risk score
which we now plan to validate on a larger melanoma
cohort.
Conclusion
Our results indicate that the CD3, CD8, CD20, and FoxP3
panel could be useful in defining the Immunscore, thanks
to its prognostic value in high risk melanoma patients.
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